SCHEMBL25867915

SCHEMBL25867915

CC(=O)/C(=C\C(=O)O)C(C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.37
ATM Q13315 1/20 0.37
KDM1A O60341 1/20 0.36
GABRP O00591 2/20 0.32
GABRD O14764 2/20 0.32
GABRA1 P14867 2/20 0.32
GABRB1 P18505 2/20 0.32
GABRG2 P18507 2/20 0.32
GABRB3 P28472 2/20 0.32
GABRA5 P31644 2/20 0.32
GABRA3 P34903 2/20 0.32
GABRA2 P47869 2/20 0.32
GABRB2 P47870 2/20 0.32
GABRA4 P48169 2/20 0.32
GABRE P78334 2/20 0.32
GABRA6 Q16445 2/20 0.32
GABRG1 Q8N1C3 2/20 0.32
GABRG3 Q99928 2/20 0.32
GABRQ Q9UN88 2/20 0.32
TP53 P04637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL346751 0.81 KDM4E (0.33) KDM4EATMKDM1AGABRPGABRD
SCHEMBL2416426 0.81 KDM4E (0.33) KDM4EATMKDM1AGABRPGABRD
SCHEMBL346752 0.81 KDM4E (0.33) KDM4EATMKDM1AGABRPGABRD
Hydrochloric Acid SCHEMBL9168486 0.79 KDM1A (0.32) KDM4EATMKDM1AGABRPGABRD
SCHEMBL28808090 0.79 KDM1A (0.32) KDM4EATMKDM1AGABRPGABRD
SCHEMBL28760214 0.77 GABRP (0.36) KDM4EATMKDM1AGABRPGABRD
SCHEMBL1426752 0.77 GABRP (0.36) KDM4EATMKDM1AGABRPGABRD
Methacrylic Acid SCHEMBL2015229 0.75 KDM1A (0.32) KDM4EATMKDM1A
SCHEMBL18283305 0.73 HCAR2 (0.34) KDM4EKDM1AALDH1A1GAAHCAR2
SCHEMBL18283306 0.73 HCAR2 (0.34) KDM4EKDM1AALDH1A1GAAHCAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239828-A1 MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-07-18 US disclosed
US-20230233689-A1 Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins UNIV YALE (US) 2023-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230233689-A1 Bifunctional Small Molecules to Target the Selective Degradation of Circulating Proteins ASGR1, LDLR, FCGR2A KDM4E 4040/4885ATM 3471/4885KDM1A 3735/4885
US-20240239828-A1 MANNOSE 6-PHOSPHATE OR ASGPR RECEPTOR BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS M6PR, ASGR1, IGF2R KDM4E 3972/4885ATM 3121/4885KDM1A 4659/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.